The total study time is 22 days. Some reimbursement is available and all testing is covered by the company. This is a one year study that involves weekly and then monthly visits to Stanford for bloodwork, ECG, physical exams, spirometry, and quality of life questionnaire completion. All testing is covered by the company. This is a three year out-patient study that involves weekly, monthly and then quarterly visits to Stanford for bloodwork, ECG, physical exams, spirometry and quality of life questionnaire completion.
All testing is covered by the company.
This 12 week study is investigating the effectiveness of the continuous subcutaneous infusion of UT 15, a prostacyclin analogue with potent vasodilatory and platelet anti-aggregatory actions, in patients with primary or secondary pulmonary hypertension. Primary outcome measures of the study include exercise capacity as measured by the 6 minute walk, cardiopulmonary hemodynamics and signs and symptoms. The study involves an inpatient stay of approximately 2 days at the beginning and end of the study and weekly to monthly visits in between. In vitro IFN-B has been shown to inhibit collagen production by fibroblasts, increase collagenase MRNA and to increase collagenase activity. Avonex is currently an approved treatment for relapsing forms of multiple sclerosis.